⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506247 | 0.80 | — | — | |
| SCHEMBL4613454 | 0.73 | CA2 (0.39) | — | |
| SCHEMBL3168818 | 0.73 | CA2 (0.39) | — | |
| SCHEMBL8866302 | 0.71 | — | — | |
| SCHEMBL2358508 | 0.71 | CA2 (0.38) | — | |
| SCHEMBL3324611 | 0.71 | CA2 (0.38) | — | |
| SCHEMBL131500 | 0.71 | — | — | |
| SCHEMBL12967705 | 0.71 | — | — | |
| SCHEMBL4542101 | 0.69 | — | — | |
| SCHEMBL1804507 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS LLC | 2015-06-18 | — | — | US | claimed |
| WO-2013066833-A1 | COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20090270497-A1 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors | PHARMACYCLICS, INC. (US) | 2009-10-29 | — | — | US | claimed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| US-7517988-B2 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2009-04-14 | — | — | US | claimed |
| US-7482466-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-20080255214-A1 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | claimed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | claimed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | claimed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20190184196-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10105552-B2 | Formulations of histone deacetylase inhibitor and uses thereof | PHARMACYCLICS LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170333731-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9492423-B2 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | PHARMACYCLICS LLC (US) | 2016-11-15 | — | — | US | disclosed |
| US-9408816-B2 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9403032-B2 | Formulations of histone deacetylase inhibitor and uses therof | PHARMACYCLICS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150335609-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | PHARMACYCLICS LLC | 2015-11-26 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS LLC | 2015-06-18 | — | — | US | disclosed |
| EP-2814493-A2 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | Pharmacyclics, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140341989-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | LES LABORATOIRES SERVIER SAS (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2099442-B1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS INC (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | disclosed |
| EP-2755648-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | Pharmacyclics, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140057862-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8603521-B2 | Formulations of histone deacetylase inhibitor and uses thereof | PHARMACYCLICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2013123413-A2 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2626067-A1 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS, INC. (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013066833-A1 | COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039488-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-8389570-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110311624-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8026371-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834054-B2 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010123507-A1 | TREATMENT OF NON-LOCALIZED INFLAMMATION WITH PAN-HDAC INHIBITORS | PHARMACYCLICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20090270497-A1 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors | PHARMACYCLICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090220454-A1 | Use of the histone deacetylase inhibitor N-hydroxy-4-[2-(3-dimethylaminobenzofuran-2-ylcarbonylamino)ethoxy]benzamide (aka CRA-24781, PCI-24781) for treating myelogenous leukemia (MML) or acute myelogenous leukemia (AML), optionally in combination therapy | PHARMACYCLICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1611088-B1 | HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS INC (US) | 2009-06-17 | — | — | EP | disclosed |
| US-7517988-B2 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7482466-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20080255221-A1 | N-hydroxy-4-[2-(benzofuran-2-ylcarbonylamino)ethylsulfonyl]-benzamide; hepatitis C; inhibitors of histone deacetylase | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255214-A1 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080153877-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |